Psoriasis: Targets and Therapy

Navigating Complexity: Real-World Evidence of Biologics in Elderly and Multimorbid Psoriasis Patients

The therapeutic landscape of psoriasis has been revolutionized by the advent of biological agents, offering unprecedented levels of skin clearance and quality of life improvement. However, randomized controlled trials often employ strict inclusion criteria, leading to the underrepresentation of specific patient subgroups commonly encountered in daily practice, such as the elderly (including the "oldest old") and patients with significant multiple comorbidities. As the global population ages and the systemic nature of psoriasis becomes increasingly evident, bridging the gap between controlled trial environments and clinical reality is imperative. This Article Collection focuses on Real-World Evidence regarding the use of biologics in these complex scenarios.